Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials

被引:18
|
作者
Payne, Jonathan M. [1 ,2 ]
Barton, Belinda [2 ,3 ]
Shores, E. Arthur [4 ]
North, Kathryn N. [1 ,2 ]
机构
[1] Childrens Hosp Westmead, Inst Neurosci & Muscle Res, Sydney, NSW 2145, Australia
[2] Univ Sydney, Fac Med, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia
[3] Childrens Hosp Westmead, Childrens Hosp Educ Res Inst, Sydney, NSW 2145, Australia
[4] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia
关键词
Neurofibromatosis type 1; Visuospatial learning; Ras-MAPK signaling cascade; CANTAB; Clinical trials; COGNITIVE FUNCTION; MEMORY; DISABILITIES; ADOLESCENTS; HIPPOCAMPUS; MECHANISMS; PLASTICITY; DEMENTIA; DEFICITS;
D O I
10.1007/s00415-012-6620-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Studies investigating behavior in mice with a heterozygous null mutation of the NF1 gene (Nf1 (+/-)) have provided critical insights into the molecular and cellular mechanisms underlying cognitive impairments associated with neurofibromatosis type 1 (NF1). Hyperactivation of the Ras-MAPK signaling cascade, which results in increased GABA-mediated inhibition and significantly reduced long-term potentiation, has been proposed as a core mechanism underlying Nf1 (+/-) mice deficits in visuospatial learning and attention. This assertion has been reinforced by preclinical trials that reveal that these impairments can be rescued both at a cognitive and cellular level. We attempted to demonstrate a phenotypic parallel between Nf1 (+/-) mice and children with NF1 using a well-validated measure of visuospatial learning. Children with NF1 (n = 71) and healthy controls (n = 29) were assessed on a computerized paired associate learning task. Interrelationships between visuospatial learning and other cognitive abilities that may influence performance, such as intelligence, attention and visuospatial function, were explored. Children with NF1 displayed significant impairments in visuospatial learning, with reduced initial retention and poorer learning across repeated trials. Importantly, we demonstrated that visuospatial learning was inferior in NF1 even after accounting for group differences in intelligence, sustained attention and visuospatial abilities. We have thus identified impaired visuospatial learning as a core phenotypic feature in children with NF1. These findings imply that hippocampal-based learning networks are dysfunctional in children with NF1 and provide validation for a primary outcome measure for clinical trials aiming to correct aberrant Ras signaling.
引用
收藏
页码:214 / 220
页数:7
相关论文
共 50 条
  • [1] Paired associate learning in children with neurofibromatosis type 1: implications for clinical trials
    Jonathan M. Payne
    Belinda Barton
    E. Arthur Shores
    Kathryn N. North
    Journal of Neurology, 2013, 260 : 214 - 220
  • [2] Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1
    van der Vaart, Thijs
    Rietman, Andre B.
    Plasschaert, Ellen
    Legius, Eric
    Elgersma, Ype
    Moll, Henriette A.
    NEUROLOGY, 2016, 86 (02) : 154 - 160
  • [3] Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1
    Ullrich, Nicole J.
    Payne, Jonathan M.
    Walsh, Karin S.
    Cutter, Gary
    Packer, Roger
    North, Kathryn
    Rey-Casserly, Celiane
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2020, 7 (02): : 245 - 249
  • [4] Neurocognitive profiles of learning disabled children with neurofibromatosis type1
    Orraca-Castillo, Miladys
    Estevez-Perez, Nancy
    Reigosa-Crespo, Vivian
    FRONTIERS IN HUMAN NEUROSCIENCE, 2014, 8
  • [5] Motor Learning in Children with Neurofibromatosis Type I
    Krab, Lianne C.
    de Goede-Bolder, Arja
    Aarsen, Femke K.
    Moll, Henriette A.
    De Zeeuw, Chris I.
    Elgersma, Ype
    van der Geest, Josef N.
    CEREBELLUM, 2011, 10 (01) : 14 - 21
  • [6] Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials
    Cannon, Ashley
    Sarin, Kavita Y.
    Petersen, Andrea K.
    Pichard, Dominique C.
    Wolters, Pamela L.
    Erickson, Gregg
    Lessing, Andres J.
    Li, Peng
    Roehl, Claas
    Rosser, Tena
    Widemann, Brigitte C.
    Blakeley, Jaishri O.
    Plotkin, Scott R.
    REiNS International Collaboration
    CLINICAL TRIALS, 2024, 21 (01) : 67 - 72
  • [7] Developmental Delays in Children With Neurofibromatosis Type 1
    Soucy, Elizabeth A.
    Gao, Feng
    Gutmann, David H.
    Dunn, Courtney M.
    JOURNAL OF CHILD NEUROLOGY, 2012, 27 (05) : 641 - 644
  • [8] Statins in Children with Neurofibromatosis Type 1: A Systematic Review of Randomized Controlled Trials
    Agouridis, Aris P.
    Palli, Nikoletta
    Karagiorga, Vasiliki-Eirini
    Konsoula, Afroditi
    Markaki, Lamprini
    Spernovasilis, Nikolaos
    Tsioutis, Constantinos
    CHILDREN-BASEL, 2023, 10 (09):
  • [9] Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1
    Payne, Jonathan M.
    Hearps, Stephen J. C.
    Walsh, Karin S.
    Paltin, Iris
    Barton, Belinda
    Ullrich, Nicole J.
    Haebich, Kristina M.
    Coghill, David
    Gioia, Gerard A.
    Cantor, Alan
    Cutter, Gary
    Tonsgard, James H.
    Viskochil, David
    Rey-Casserly, Celiane
    Schorry, Elizabeth K.
    Ackerson, Joseph D.
    Klesse, Laura
    Fisher, Michael J.
    Gutmann, David H.
    Rosser, Tena
    Packer, Roger J.
    Korf, Bruce
    Acosta, Maria T.
    North, Kathryn N.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2019, 6 (12): : 2555 - 2565
  • [10] Recommendations for Social Skills End Points for Clinical Trials in Neurofibromatosis Type 1
    Janusz, Jennifer A.
    Klein-Tasman, Bonita P.
    Payne, Jonathan M.
    Wolters, Pamela L.
    Thompson, Heather L.
    Martin, Staci
    de Blank, Peter
    Ullrich, Nicole
    del Castillo, Allison
    Hussey, Maureen
    Hardy, Kristina K.
    Haebich, Kristina
    Rosser, Tena
    Toledo-Tamula, Mary Anne
    Walsh, Karin S.
    NEUROLOGY, 2021, 97 (07) : S73 - S80